Thermal

Thermal Wrapped 2025. 50+ milestones announced. 200+ media placements. 35+ speaking events. From CRISPR to AI in health and bio to longevity: we shaped the stories that moved science forward. Looking ahead, we're bullish on 2026. CRISPR is evolving from one-off cures into scalable genetic medicines across both rare and common disease. AI is transforming not just drug discovery but development, trials, and healthcare delivery. More breakthroughs will advance through the clinic and reach patients. The best stories are still ahead. If you need to level up your company's PR strategy, let's talk. As the agency of Nobel laureates and the world's most innovative scientists, biotechs, and VCs, Thermal can help.

@TheTimes featured Ginkgo on how AI and cloud labs are accelerating the pace of scientific discovery. In the story, @jrkelly shares what Ginkgo’s autonomous lab Nebula has achieved with @OpenAI’s models, the future of AI-driven science, and his reality check on biosafety risks. Read the full feature by @dannyforston: hubs.ly/Q04fcrBt0 Use our Cloud Lab today: hubs.ly/Q04fcr_G0

Strand Therapeutics is heading to the @MilkenInstitute Global Conference 2026 in Los Angeles. On May 4 at 10 a.m. PT, our CEO and co-founder, @DrSynbio, will join an invitation-only panel on sustaining American leadership in biomedical innovation. He’ll be joined by @SecAzar, 24th U.S. Secretary of Health and Human Services; @mmrozenman, CFO and CBO of @insitro; and @rtnarch, co-founder and managing director of ARCH Venture Partners. The session will be moderated by @SungHeeTweets, managing director of FasterCures at Milken Institute Health. Looking forward to continuing the conversation at #MIGlobal. milkeninstitute.org/content-hub/ev…

Our thanks to Kia MacPherson and the Biocom team for their partnership.

🔥 @RonAlfa, Co-Founder & CEO of @NOETIK_ai, sat down with Kim Branson of @GSK for a fireside chat anchored in their recent partnership and what it signals for the future of AI-driven drug discovery.

Thermal clients took the stage at @Biocom's Converge Summit last week. Hear what they had to say in the 🧵:

Just over a year ago, baby KJ Muldoon received the first infusion of a personalized genetic therapy designed specifically for his life-threatening disease. In Barbara Nasto's new featured article "The patient is now in the room" in @NatureMedicine, Nobel laureate, CRISPR pioneer and Innovative Genomics Institute founder Jennifer Doudna reflects on where that story has arrived: "He is now considered functionally cured...it's so inspiring and it's so motivating." The feature uses KJ's case to ask a bigger question: if this worked for one patient, what does it take to work for thousands? Nasto traces the regulatory, technological, and cultural forces pushing patient-driven research from a rare-disease exception into standard practice — and how much work remains. Our thanks to Barbara for telling this story with the depth it deserves. nature.com/articles/s4159…

Next month, join us at the 2026 @ASGCTherapy Annual Meeting and @EASCongress !

We're excited to welcome Kunal Bhatia to Strand as Chief Financial Officer. Kunal brings 15 years of investment banking experience advising biopharmaceutical companies on financing and business development, most recently as interim CFO and CBO to a portfolio of life sciences companies. His appointment comes as Strand advances a growing pipeline – STX-001 clinical data, STX-003 heading to the clinic in mid-2026, and our in vivo CAR-T program – and builds on a $153M Series B. As we enter this next chapter, Kunal's expertise in capital formation and strategic partnerships positions Strand to keep advancing our mission of integrating programmable genetic medicines into the core of modern therapeutics. Read more: businesswire.com/news/home/2026…

ICYMI: Our CTO @edunov spoke at @Biocom #ConvergeSummit on how Genesis is scaling molecular AI foundation models with physics-generated synthetic data to predict drug-protein interactions with the accuracy needed for real-world drug programs.

Noetik’s AI value proposition: “cohort selection” “When I do my drug’s clinical trials, who should participate?” Obviously, if you get that wrong, then your drug won’t “work,” even if it actually works! Ron Alfa explained to us how they do this using cheap imaging 1/

The best conversations happen with your running shoes on. We're hosting @Techweek_ events in both Boston and New York this year, and we'd love for you to join us. We'll kick off with a 5k group run along the river (all paces welcome), then head back to our office for breakfast. 📍 Boston — May 27 along the Charles River: partiful.com/e/FJXCHsTzgGQQ… 📍 New York — June 2 along the Hudson River Greenway: partiful.com/e/Dy7rUqrhVPwy… More info and links to register above. #BOSTechWeek #NYTechWeek

We’re proud to announce a full slate of activities at #ASGCT2026 next month, including two Symposia talks and four oral and poster presentations that highlight our progress in AI-designed AAV capsids for improved gene delivery. We’re honored to sponsor this year’s ASGCT Momentum Gala on May 12. More details here: businesswire.com/news/home/2026…

Generating CAR-T cells inside the body, without removing and reengineering a patient's cells, has long been one of cell therapy's most persistent unsolved challenges. We're presenting data at #ASGCT2026 with data that shows how programmable mRNA can deliver on it. Ashlesha Odak, PhD will go over preclinical findings from the circRNA-LNP platform showing near-complete B cell depletion in non-human primates following IV dosing, with programmable safety controls built in. Presentation details below. Full abstract here: annualmeeting.asgct.org/abstracts Abstract Title: Programmable circRNA-tLNP platform enables efficient in vivo CAR-T cell programming and robust activity in a NHP model Session Type: Oral Session Name: LNPs for in vivo CAR-T applications Date and Time: Tuesday, May 12, 2026, at 9:00-9:15 am ET Location: MCEC Room 210 ABC (Level 2)

Congratulations to our co-founder and CEO @DrSynbio, named a finalist for the @EY_US Entrepreneur Of The Year 2026 New England Award. Jake built Strand on a single conviction: mRNA could be programmed to know the difference between healthy and diseased cells. That idea is what this recognition reflects, and what we believe the future of genetic medicine will be built on. Congrats, Jake!

We worked with @OpenAI to connect AI to our autonomous lab. Read all about it in a new article from @AIMmediahouse: 🟢 How AI models designed experiments, generated protocols, and analyzed results from lab runs on Nebula, our autonomous lab 🟢 Results that improved cell-free protein synthesis #CFPS costs by 40% over the state-of-the-art 🟢 Shoutouts from @joyjiao12 and Yunyun Wang on the OpenAI Podcast hubs.la/Q04dn0QR0

AI scientists are one of @techreview’s top 10 things that matter in AI right now. Read about how the autonomous lab plugs into AI-powered science today, including our work that reduced the cost of cell-free protein synthesis by 40%. Story by @grace_huckins: hubs.la/Q04dclGV0

🗓️We're expanding our presence at conferences, roadshows, and more as we recruit innovative scientists like you to incorporate the Nautilus Voyager™ Platform into their workflows and join the Iterative Mapping Early Access Program. To see where we'll be in the coming months, check out our Events Page: nautilus-21430832.hs-sites-na2.com/nautilus-events ✍️And if you'd like to work with us to set up an event at your organization, fill out the form at the bottom of the page, and we'll be in touch. We hope to see you soon!